Loading live market data…
Loading live market data…
Every ratio from the Fundamental Analysis track, computed on a real company and annotated with what the number actually means. Then the three financial statements, so you can do the cash-flow check yourself.
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance. In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty clinics, dental and dialysis facilities, and preventive care; day surgery, diabetes management, and cradle and fertility centers; and Apollo 24/7, a digital health mobile platform that provides teleconsultations, online pharmacy deliveries, home diagnostics, and insurance services. Further, the company engages in the business of bio-banking of tissues. It serves patients, corporate clients, and the government and public sectors. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.
How the price compares to earnings, assets and cash generation.
You are paying 58.8 years of current profit for each share. The earnings yield is 1.7%. The tracked Pharma & Healthcare median is 41.2× (n=7), so this trades richer than its peers.
The market values the company at 12.5× its accounting net worth. High is normal for asset-light businesses and unusual for banks.
This is the only common multiple that accounts for debt — it is what an actual acquirer would look at, because they would inherit the borrowings.
Pays 0.22% of the current price out each year. Remember that yield rises when price falls — check the dividend is covered by cash flow.
Based on the next-year earnings estimate — 42.1× against 58.8× trailing. A forward P/E well below trailing is pricing in an earnings jump; treat the forecast with caution.
You pay 4.7× annual sales. Useful when earnings are depressed or negative and P/E breaks down — but a high multiple needs high margins to justify it.
Returns on capital and margins, the numerical shadow of a moat.
Earns ₹22.5 of profit a year for every ₹100 of shareholders' money. Always check how much of this comes from leverage rather than the business.
ROE is 13.4 points above ROA — a large gap, meaning leverage is doing much of the work.
Keeps ₹12.1 of operating profit from every ₹100 of sales. Compare only against companies in the same industry.
Sustained high net margins are evidence that something is stopping competitors from competing the profits away.
Keeps ₹35.5 of gross profit per ₹100 of sales, before operating costs. A high, stable gross margin is the clearest single sign of pricing power.
Leverage and liquidity. This is where fragility shows up first.
A conservative balance sheet that can absorb a downturn without a crisis.
Short-term obligations are comfortably covered by short-term assets.
The current ratio stripped of inventory — a stricter test of whether near-term bills can be met without selling stock. Below 1 means the company is relying on inventory turning to cash.
Against cash of ₹2381.10 Cr. Net debt is what matters, not gross borrowings.
Spends more on capital than it generates from operations. Fine during an expansion phase, dangerous if it persists.
Revenue and earnings momentum, and how the two compare.
Ask where the growth came from: more volume, higher prices, or an acquisition. They are very different in quality.
Profits are growing faster than sales — margins are expanding, which is the sign of genuine operating leverage.
EBITDA of ₹3948.20 Cr and operating cash flow of ₹3023.70 Cr.
Not available.
The figures quoted per share, and how much profit is handed back to owners.
₹156.39 of profit earned per share over the last twelve months. Price divided by this is the trailing P/E.
The accounting net worth behind each share is ₹737.64; price-to-book compares the market price with this.
Pays out 13% of profit as dividends and retains the rest. Above roughly 85% leaves little to reinvest and is hard to sustain through a weak year.
Market cap plus net debt — closer to what an acquirer actually pays. Against a market cap of ₹1,32,282 Cr.
Return on equity splits into three drivers. The identical ROE can be a genuinely great business or a heavily borrowed ordinary one.
The return leans on the business itself — margin and asset turnover — rather than on heavy borrowing, which is the healthier source of a high ROE.
Nine yes/no tests of profitability, funding and efficiency across the last two years; higher is stronger. A test is dropped only where the data is missing, so the score is out of 9.
NOPAT ÷ invested capital. What the business earns on all its capital, debt and equity — harder to flatter with leverage than ROE.
A company creates value only when ROIC clears its cost of capital (WACC) — judge this figure against the company’s cost of capital, and watch the trend across years.
Five weighted ratios in one bankruptcy early-warning number. Read the zone and, over time, the trend.
Comfortably in the safe zone — low near-term distress risk on this measure. Still worth tracking the trend.
Reported figures, most recent year first. All values in rupees.
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | ₹24910.60 Cr | ₹21526.70 Cr | ₹18862.30 Cr | ₹16444.80 Cr |
| Cost of revenue | ₹13075.60 Cr | ₹11310.00 Cr | ₹9805.50 Cr | ₹8574.30 Cr |
| Gross profit | ₹11835.00 Cr | ₹10216.70 Cr | ₹9056.80 Cr | ₹7870.50 Cr |
| Operating expenses | ₹8931.80 Cr | ₹7940.90 Cr | ₹7349.50 Cr | ₹6421.30 Cr |
| Operating income | ₹2903.20 Cr | ₹2275.80 Cr | ₹1707.30 Cr | ₹1449.20 Cr |
| Interest expense | ₹356.10 Cr | ₹422.50 Cr | ₹410.10 Cr | ₹313.70 Cr |
| Pre-tax income | ₹2660.90 Cr | ₹2039.10 Cr | ₹1380.50 Cr | ₹1143.70 Cr |
| Tax | ₹658.20 Cr | ₹534.00 Cr | ₹445.50 Cr | ₹256.20 Cr |
| Net profit | ₹1941.70 Cr | ₹1445.90 Cr | ₹898.60 Cr | ₹819.10 Cr |